A team at Children’s National Research and Innovation Campus is working on something new that could change the way we pinpoint pain, and how effectively we treat it. The technology could give hope to ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

This 11-point scale ranges from 0 (no pain) to 10 (worst pain imaginable). The suzetrigine arm showed a statistically significant and clinically meaningful within-group reduction from baseline in pain ...

In a small clinical study, researchers in the US examined the nature of new-onset pain reported by people with long COVID and explored potential associations between long COVID symptoms and pain.

A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...

In the midst of a sexual recession, young adults are having rougher sex than ever before. “Sex has not always been this rough ...

A football coach and Mr. Universe winner who'd been putting off a hip replacement found himself back on the field in 4 days ...